- Home
- GWRS vs DMAC Comparison
GWRS vs DMAC Comparison
Compare GWRS & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRS
- DMAC
- Stock Information
- Founded
- GWRS 2003
- DMAC 2000
- Country
- GWRS United States
- DMAC United States
- Employees
- GWRS N/A
- DMAC N/A
- Industry
- GWRS Water Supply
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- GWRS Utilities
- DMAC Health Care
- Exchange
- GWRS Nasdaq
- DMAC Nasdaq
- Market Cap
- GWRS 265.4M
- DMAC 310.1M
- IPO Year
- GWRS 2010
- DMAC N/A
- Fundamental
- Price
- GWRS $9.95
- DMAC $7.01
- Analyst Decision
- GWRS
- DMAC Strong Buy
- Analyst Count
- GWRS 0
- DMAC 3
- Target Price
- GWRS N/A
- DMAC $12.33
- AVG Volume (30 Days)
- GWRS 41.1K
- DMAC 440.7K
- Earning Date
- GWRS 11-05-2025
- DMAC 11-12-2025
- Dividend Yield
- GWRS 3.06%
- DMAC N/A
- EPS Growth
- GWRS N/A
- DMAC N/A
- EPS
- GWRS 0.22
- DMAC N/A
- Revenue
- GWRS $54,270,000.00
- DMAC N/A
- Revenue This Year
- GWRS $8.11
- DMAC N/A
- Revenue Next Year
- GWRS $6.71
- DMAC N/A
- P/E Ratio
- GWRS $45.60
- DMAC N/A
- Revenue Growth
- GWRS 4.33
- DMAC N/A
- 52 Week Low
- GWRS $9.27
- DMAC $3.19
- 52 Week High
- GWRS $13.98
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- GWRS 54.15
- DMAC 67.16
- Support Level
- GWRS $9.64
- DMAC $6.83
- Resistance Level
- GWRS $9.93
- DMAC $7.46
- Average True Range (ATR)
- GWRS 0.23
- DMAC 0.42
- MACD
- GWRS 0.04
- DMAC 0.08
- Stochastic Oscillator
- GWRS 97.14
- DMAC 79.58
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.